BURLINGAME, California – Oct 19, 2020
Genesis Therapeutics, a pioneer in AI-driven drug discovery, has announced a multi-target collaboration with Genentech, a member of the Roche Group. This partnership will leverage Genesis’ cutting-edge AI platform to accelerate the identification and development of breakthrough therapeutics across multiple disease areas. The alliance underscores the growing role of artificial intelligence in transforming the biopharmaceutical landscape.
Genesis Therapeutics’ AI Technology to Power Genentech’s Drug Discovery Efforts
At the heart of this collaboration is Genesis Therapeutics’ proprietary AI platform, which integrates graph machine learning and neural networks to optimize key drug properties such as potency, selectivity, and absorption, distribution, metabolism, and excretion (ADME). By combining molecular dynamics with deep learning, the platform enhances drug-target predictions with unprecedented precision.
“This collaboration with Genentech enables us to maximize the potential of our AI-driven platform alongside their world-class expertise in molecular innovation and structural biology,” said Evan Feinberg, Ph.D., co-founder and CEO of Genesis Therapeutics. “Together, we are redefining what is possible in AI-powered drug discovery to accelerate the development of transformative therapies for patients.”
Genentech and Genesis Therapeutics Strengthen AI’s Role in Biopharma Innovation
Under the agreement, Genesis Therapeutics will receive an upfront payment and is eligible for preclinical, clinical, and regulatory milestone payments, along with potential royalties on Genentech’s future sales of approved drugs emerging from the collaboration.
James Sabry, M.D., Ph.D., Global Head of Roche Pharma Partnering, emphasized the strategic impact of AI-driven discovery, stating, “Artificial intelligence is opening doors to novel therapeutic possibilities that were previously out of reach. We are excited to work with Genesis Therapeutics to develop the next generation of innovative medicines for patients in need.”
Genesis Therapeutics’ Molecular AI Platform Sets a New Standard for Drug Discovery at Genentech
Genesis Therapeutics’ AI-driven Molecular AI platform, including its Dynamic PotentialNet algorithm, represents a paradigm shift in computational drug discovery. By analyzing drug-target interactions as flexible, spatial graphs, the platform surpasses traditional modeling approaches and unlocks new opportunities for both well-characterized and previously undruggable targets.
Through this collaboration, Genentech and Genesis Therapeutics are setting a bold precedent for AI’s role in biopharmaceutical innovation—where cutting-edge technology and deep scientific expertise converge to accelerate the discovery of life-changing medicines.
About Genesis Therapeutics
Genesis Therapeutics is an AI-driven biotech company using its GEMS platform to design and optimize small molecule therapeutics for complex targets. Combining advanced AI, machine learning, and experimental validation, Genesis accelerates drug discovery from its headquarters in Burlingame, CA, and San Diego lab. Backed by $300M+ in funding, it is building a pipeline of breakthrough therapies. More about news
By
